Rajavelu Esther 4
4 · Spero Therapeutics, Inc. · Filed Feb 5, 2025
Insider Transaction Report
Form 4
Rajavelu Esther
See Remarks
Transactions
- Award
Common Stock
2025-02-03+266,139→ 645,409 total - Award
Common Stock
2025-02-03+100,000→ 745,409 total - Sale
Common Stock
2025-02-05$0.78/sh−20,689$16,137→ 724,720 total
Footnotes (3)
- [F1]Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 3, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
- [F2]Each RSU represents the right to receive one share of common stock upon vesting. The RSUs shall vest in full on February 3, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
- [F3]The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2024.